CorMedix, Inc. (NASDAQ:CRMD) Q1 2025 Earnings Conference Call May 6, 2025 8:30 AM ET
Company Participants
Dan Ferry – LifeSci Advisors
Joe Todisco – Chief Executive Officer
Matt David – Executive Vice President and Chief Financial Officer
Liz Hurlburt – Executive Vice President, Chief Clinical Strategy and Operations Officer
Conference Call Participants
Gregory Renza – RBC Capital
Roana Ruiz – Leerink Partners
Leszek Sulewski – Truist Securities
Serge Belanger – Needham & Company
Operator
Good day and welcome to the CorMedix, Inc. First Quarter 2025 Financial Results Conference Call. All participants will be in listen-only mode. [Operator Instructions] Please note this event is being recorded.
I would now like to turn the conference over to Dan Ferry, LifeSci Advisors. Please go ahead.
Dan Ferry
Good morning and welcome to the CorMedix first quarter 2025 earnings conference call. Leading the call today is Joe Todisco, Chief Executive Officer of CorMedix. He is joined by Dr. Matt David, Executive Vice President and CFO; Beth Zelnick Kaufman, EVP and Chief Legal and Compliance Officer; Liz Hurlburt, EVP and Chief Clinical Strategy and Operations Officer; and Erin Mistry, EVP and Chief Commercial Officer.
Before we begin, I would like to remind everyone that during the call, management may make what are known as forward-looking statements within the meeting set forth in the Private Securities Litigation Reform Act of 1995. These statements are statements other than statements of historical fact regarding management’s expectations, beliefs, goals and plans about the company’s prospects and future financial position. Actual results may differ materially from the estimates and projections on which these statements are based due to a variety of important factors including the risks and uncertainties described in greater detail in CorMedix filings with the SEC, which are available free of charge at the SEC’s website or upon request from CorMedix. CorMedix may not actually achieve
Credit: Source link
